CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Paracetamol +1 moredrug
Likely dose
Paracetamol 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04028596
NCT04028596Phase 2Completed
CompareCT.gov

StudY of Effect of Nimodipine and Acetaminophen on Postictal Symptoms After ECT

Rijnstate Hospital·interventional·Posted Jul 22, 2019·Updated Nov 18, 2023

In Brief

A Phase 2 clinical trial evaluating Paracetamol and Nimotop for Epilepsy and 3 related conditions. Completed, enrolled 34 participants across 1 site.

Detailed Summary

In this clinical trial, postictal phenomena (i.e., headache, delirium) will be investigated after administration of acetaminophen and nimodipine in depressed patients receiving electroconvulsive therapy (ECT). Postictal phenomena are thought to result from decreased cerebral blood flow and decreased oxygen concentration in the brain. It is expected that acetaminophen and nimodipine will reduce these postictal phenomena, compared to no treatment, because they target these mechanisms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy, Depression, Postictal Delirium, Electroconvulsive Therapy
CountriesNetherlands
CollaboratorsUniversity of Twente, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 22, 2019
Enrollment StartDec 5, 2019
Primary CompletionDec 30, 2022
Study CompletionApr 15, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.9 years ago

Interventions

Paracetamoldrug

once, 1000mg, 2 h before ECT session

Nimotopdrug

once, 60mg, 2 h before ECT session